Becton Dickinson

Q4 FY2026
Speakers

Nov 5, 2026 · 57 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Hello, and welcome to BD's fourth quarter and full year fiscal 2026 earnings call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com, or by phone at 800-677-7085 for domestic calls, and area code plus one four zero two-2200665 for international calls. For For today's call, all parties have been placed in a listen-only mode until the question and answer session.

I will now turn the call over to
Sean Beck, Senior Vice President, Investor Relations.

Passages & reports (3)
  • Hello, and welcome to BD's fourth quarter and full year fiscal 2026 earnings call. At the …
  • 800-677-7085 for domestic calls, and area code plus one four zero two-2200665 for internat…
  • Sean Beck, Senior Vice President, Investor Relations.

Speaker 1

Unverified voice label

Good morning and welcome to BD's Earnings Call. I'm Sean Bevick, Senior Vice President of Investor Relations. Thank you for joining us. This call is being made available via audio webcast at BD.com. Earlier this morning, BD released its results for the fourth quarter and full year fiscal twenty-six. The press release and presentation can be accessed on the IR website at investors.bd.com. Leading today's call are Tom Poland, BD's Chairman, Chief Executive Officer and President, ?and Vitor Roque, Executive Vice President and Chief Financial Officer.

Before we get started, I want to remind you that we will be making forward-looking statements. You can read the disclaimer in our earnings release and the disclosures in our SEC filings on our investor relations website. Unless otherwise specified, all comparisons will be made on
a on year basis versus the relevant fiscal period. Revenue percentage changes are on an FX neutral basis unless otherwise noted.

Also, references to adjusted EPS refer to adjusted diluted EPS.
?The financials discussed here and included in the earnings release are presented on a continuing operations basis. Prior periods have been recast to reflect the spin-off of our life sciences business and combination with waters, which is accounted for as discontinued operations. Reconciliations between GAAP and non-GAAP measures are included in the appendices of our earnings release and presentation.

With that, I will turn it over to Tom.
?Thank you, Sean,

Passages & reports (10)
  • Good morning and welcome to BD's Earnings Call. I'm Sean Bevick, Senior Vice President of …
  • be accessed on the IR website at investors.bd.com. Leading today's call are Tom Poland, BD…
  • and
  • Vitor Roque, Executive Vice President and Chief Financial Officer. Before we get started, …
  • a on year basis versus the relevant fiscal period. Revenue percentage changes are on an FX…
  • The
  • financials discussed here and included in the earnings release are presented on a continui…
  • earnings release and presentation. With that, I will turn it over to Tom.
  • Thank
  • you, Sean,

Speaker 2

Unverified voice label

and good morning, everyone. Earlier today, we reported strong Q4 results with revenue of $5.3 billion up 5.6% and 27.3% growth in adjusted EPS to $4.15. For the full year, we delivered $19.5 billion in revenue, up 3.9% and 6.7% growth in adjusted EPS to $12.70. Growth remained broad based with momentum across all our businesses. Excluding the Alaris prior year comparison, we delivered high single digit revenue growth in Q4 and solid mid single digit growth for the full year.

Growth was led by the key platforms where we've been investing, including Advanced Patient Monitoring, PureWIC, Advanced Tissue Regeneration, biologic drug delivery, and ROA pharmacy automation, all of which delivered double-digit growth with accretive margins in both Q4 and the full
year. Importantly, fiscal 26 marks a significant milestone, completing BD's transformation to a more focused MedTech company with the separation of our life sciences business. ?

New
BD is doing exactly what we designed it to ?do, demonstrating the growth and earnings potential of our focused portfolio through commercial and innovation momentum across our key growth platforms, delivering strong operational execution and the expanding impact of BD Excellence. Before we get into more details on the quarter, I want to highlight our recent landmark partnership with the U.S. government, which reflects BD's important role in the U.S.

healthcare infrastructure and a shared commitment to expand domestic manufacturing capacity and strengthen access to essential medical technologies. Through this agreement, we committed to invest $19 billion in the U.S.

Passages & reports (9)
  • and good morning, everyone. Earlier today, we reported strong Q4 results with revenue of $…
  • 3.9% and 6.7% growth in adjusted EPS to $12.70. Growth remained broad based with momentum …
  • full year. Growth was led by the key platforms where we've been investing, including Advan…
  • year. Importantly, fiscal 26 marks a significant milestone, completing BD's transformation…
  • New
  • BD is doing exactly what we designed it to
  • do,
  • demonstrating the growth and earnings potential of our focused portfolio through commercia…
  • partnership with the U.S. government, which reflects BD's important role in the U.S. healt…

over several years, with $3 billion of the overall investment directed toward manufacturing expansion. Importantly, this does not represent incremental investment for BD, rather, a reprioritization of investments toward the U.S. to support domestic manufacturing and supply chain resiliency. The partnership also provides relief from future tariffs imposed under Section 232 ?on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD's achievement of agreed milestones.

We've already mobilized the organization
?and begun taking action to deliver on these commitments. Turning to our new BD strategy, we're seeing clear progress against our three strategic pillars: compete, innovate, and deliver. Our growing commercial, innovation, and operational capabilities, our strengthening the quality of our growth, while improving earnings power and cash flow. Starting with compete, we've been raising the bar on commercial execution across BD, investing in every part of the commercial flywheel.

That spans talent, AI sales tools, a disciplined sales process, and new
pay-for-performance compensation plans, all powered by BD Excellence ?and a relentless focus on solving customer challenges with speed and urgency. In Q4, this translated into measurable outcomes across the company. Within connected care, commercial execution continued to drive share gains and new adoption across all platforms. In advanced patient monitoring, Salesforce investments are driving uptake of Hemosphere Ulta that contributed to strong capital growth in Q4.

APM continues to perform well ahead of the deal model, generating one of its highest annual growth rates in the last 20 years, while significantly expanding margins under BD's ownership
?by applying BD excellence in APM manufacturing. Alaris finished the year with strong competitive momentum, gaining additional share in Q4 and more than 250 basis points for the full year. Dispensing also continued to gain share.

With strong Pixis Pro order momentum and
a 95% attachment rate of our new Encata AI platform. This strong early adoption reflects high customer interest in our new BD AI platform and supports our strategy to build recurring software, analytics, and AI revenue. In pharmacy automation, incremental investments we made coming into the year are delivering results. We're seeing increased central fill win rates and an improving growth outlook aided by the recent U.S.

launch of BD VMAX.
?We exited the year with strong commercial momentum, winning all six central fill opportunities we competed for in Q4, with VMAX attached to every sale, reinforcing the strength of our portfolio in the growing U.S. healthcare system's central fill market. In biopharma systems, we expanded our position in next generation biologic drug delivery, including continued momentum in delivering GOP1 therapies. In interventional, incremental commercial investments are translating to stronger growth, with PI accelerating each quarter throughout the year.

In UCC, Pure Wick delivered another quarter of
double-digit growth, driven by continued adoption, competitive wins, and momentum in the VA channel. Across the portfolio, we're seeing our commercial investments translate into stronger growth and competitive performance. We've added resources in priority areas, introduced new tools, applied BD excellence to commercial execution, and better aligned incentives with our growth priorities. These actions are raising execution across new BD.

Our second priority is innovate. We're concentrating investments in attractive markets where healthcare needs BD most and where we believe BD can create
sustainable competitive advantage. ?This is in connected care, enabling the shift to newer low-cost settings, and advancing the treatment of chronic disease. Earlier this year, we moved more RD resources and decision making closer to the businesses. ?We increased investments behind our six key growth platforms, and our pipeline is expanding.

We also deployed BD Excellence into RD this year and are introducing new products faster, having compressed launch times by an average of 10 months. In Q4, we received FDA approval for
Liberty Tip STEMCraft, and we're seeing strong customer interest. ?In a market that's seen limited innovation for many years, Liberty brings enhanced ease of use, ?the broadest range of lengths, and compelling clinical data, broadening BD's presence in the approximately $2 billion global venous market, which is growing high single digits. ?

We
recently received 510K clearance for phasics ST peristomal, a first of its kind resorbable mesh designed specifically for peristomal hernial repairs. ?It's an underserved market with significant unmet clinical needs. ?With the launch expected in the first half of fiscal 27, this innovation further expands our advanced tissue regeneration portfolio and strengthens our position in the $1.8 billion served market. We're increasingly seeing the benefits of the strategic choices and investments we've made over the last several years.

Combined with our strength and innovation capabilities and execution, we're building a robust pipeline
?and look forward to sharing more at our upcoming investor day next month. Our third priority, deliver, is about operational excellence at scale. ?It's about improving quality, service, productivity, margin, and cash flow. Through BD Excellence, we've built one of the most resilient supply chains in our industry, which combined with our scale, has become a meaningful competitive advantage.

In fiscal twenty six,
?we delivered approximately 8% gross productivity in our plants with customer service levels above 90%. This was driven by more than 2,000 KIZAM events, resulting in higher manufacturing efficiencies and raw material savings, as well as ongoing network optimization. We are also generating value from the $200 million cost out program launched at the beginning of fiscal 26, with 100% of the savings now identified.

Turning to capital allocation,
?our discipline framework remains unchanged. Importantly, we're seeing our operational progress translate into stronger cash generation. As free cash flow improves, so does our capacity to invest organically, return capital to shareholders, and pursue focused tuck-in MA. This will continue to increase as we drive towards our 90% free cash flow conversion target over time. In summary, fiscal 26 was an important year for BD.

We completed our portfolio transformation to a pure play med tech company. We've strengthened execution and increasingly saw the benefits of the strategic choices and investments we've
made over the last several years. Our differentiated growth platforms are strengthening our portfolio and expanding our opportunities for growth. We enter fiscal 27 with a more focused portfolio, and we have confidence in the underlying trajectory of new BD and our path towards sustainable mid-single-digit growth.

Looking ahead, we see a compelling opportunity to combine that growth with continued earnings expansion and a step change in cash flow generation to drive long-term value creation. We are still early in realizing the full potential of new BD,
?and we look forward to laying out that opportunity in greater detail at our investor day on December 10th. With that, I'll turn it over to Vitor to provide more detail on our financial performance and guidance.

Thanks, Tom, and good morning, everyone. We delivered a strong quarter with $5.3 billion
?in revenue up 5.6%. Excluding the Alaris prior year comparison, revenue growth was high single digits. As Tom highlighted, performance was broad-based, driven by continued double digit growth across multiple key platforms

Passages & reports (53)
  • over several years, with $3 billion of the overall investment directed toward manufacturin…
  • The partnership also provides relief from future tariffs imposed under Section 232
  • on
  • covered BD products and inputs, subject to the final scope and implementation of any futur…
  • and
  • begun taking action to deliver on these commitments. Turning to our new BD strategy, we're…
  • growth, while improving earnings power and cash flow. Starting with compete, we've been ra…
  • pay-for-performance compensation plans, all powered by BD Excellence
  • and
  • a relentless focus on solving customer challenges with speed and urgency. In Q4, this tran…
  • Salesforce investments are driving uptake of Hemosphere Ulta that contributed to strong ca…
  • by
  • applying BD excellence in APM manufacturing. Alaris finished the year with strong competit…
  • a 95% attachment rate of our new Encata AI platform. This strong early adoption reflects h…
  • made coming into the year are delivering results. We're seeing increased central fill win …
  • We
  • exited the year with strong commercial momentum, winning all six central fill opportunitie…
  • in next generation biologic drug delivery, including continued momentum in delivering GOP1…
  • double-digit growth, driven by continued adoption, competitive wins, and momentum in the V…
  • BD excellence to commercial execution, and better aligned incentives with our growth prior…
  • sustainable competitive advantage.
  • This
  • is in connected care, enabling the shift to newer low-cost settings, and advancing the tre…
  • We
  • increased investments behind our six key growth platforms, and our pipeline is expanding. …
  • Liberty Tip STEMCraft, and we're seeing strong customer interest.
  • In
  • a market that's seen limited innovation for many years, Liberty brings enhanced ease of us…
  • the
  • broadest range of lengths, and compelling clinical data, broadening BD's presence in the a…
  • We
  • recently received 510K clearance for phasics ST peristomal, a first of its kind resorbable…
  • It's
  • an underserved market with significant unmet clinical needs.
  • With
  • the launch expected in the first half of fiscal 27, this innovation further expands our ad…
  • Combined with our strength and innovation capabilities and execution, we're building a rob…
  • and
  • look forward to sharing more at our upcoming investor day next month. Our third priority, …
  • It's
  • about improving quality, service, productivity, margin, and cash flow. Through BD Excellen…
  • we
  • delivered approximately 8% gross productivity in our plants with customer service levels a…
  • generating value from the $200 million cost out program launched at the beginning of fisca…
  • our
  • discipline framework remains unchanged. Importantly, we're seeing our operational progress…
  • our 90% free cash flow conversion target over time. In summary, fiscal 26 was an important…
  • made over the last several years. Our differentiated growth platforms are strengthening ou…
  • growth. Looking ahead, we see a compelling opportunity to combine that growth with continu…
  • and
  • we look forward to laying out that opportunity in greater detail at our investor day on De…
  • in
  • revenue up 5.6%. Excluding the Alaris prior year comparison, revenue growth was high singl…

Speaker 1

and strong ?US performance.

Passages & reports (3)
  • and strong
  • US
  • performance.

Speaker unclear

?Medical Essentials grew

Passages & reports (1)
  • Medical Essentials grew

Speaker 3

Unverified voice label

5.9%.

Passages & reports (1)
  • 5.9%.

Speaker unclear

?In MDS, solid mid single digit

Passages & reports (1)
  • In MDS, solid mid single digit

Speaker 3

growth was ?driven by share gains and health utilization across the vascular access management portfolio. In specimen management, high single digit growth was driven by share gains across the BD vacuiner portfolio, new supply capacity, and incremental demand as customers continue to work through competitor disruptions. Connected care grew 2.1%, led by double digit growth in advanced patient monitoring, with strength in both capital and consumables.

MMS declined low single digits due to difficult prior year comparison in Alaris Capital. Excluding the Alaris comparison, MMS
delivered mid-single-digit growth, driven by strong infusion sets performance from Alaris share gain pull-through and strength in role of pharmacy automation. Biopharma systems grew 7%, driven by continued double-digit growth in biologics, led by GLP1s and moderating vaccine headwind. Interventional grew 7.6%, with high single-digit growth in peripheral intervention and UCC and solid mid-single-digit growth in surgery.

In PI, growth was led by peripheral vascular disease and oncology, reflecting strong commercial execution in new product
launches. UCC was led by continued double-digit growth in PURIC, while surgery benefited from double-digit growth in advanced tissue regeneration. Turning to the PL, adjusted growth margin was 56.8%, and adjusted operating margin was 28.6%, up 180 and 280 basis points respectively versus the prior year. Margins benefited from productivity gains through BD excellence and favorable mix while we continue to invest in selling and RD to support our long-term growth strategy.

Adjusted EPS was $4.15,
up 27.3% and ahead of our expectations, reflecting our strong revenue performance and disciplined execution. ?For the full year, adjusted growth margin was 55.1% and adjusted operating margin was 25%, down 10 and 20 basis points, respectively, versus the prior year. This was driven by a 90 basis point impact of tariffs, mostly offset by our work to be the excellence and favorable mix.

Adjusted EPS was $12.70, up 6.7%. Turning to cash flow and capital allocation, we are encouraged by the progress we made in fiscal 26
?and the momentum heading into 27. Improving free cash flow conversion is expanding our financial flexibility, enabling us to invest in growth, return capital to shareholders, and pursue focus stuck in MA. Full year free cash flow was $2.9 billion, an increase of 42% versus the prior year.

This reflects lower working capital and non operating cash items such as allowage remediation outlays, including separation costs, free cash flow conversion increased from approximately 57% to 74% in fiscal 26, and we expect another meaningful step up this
?year. In fiscal 26, we returned $3.6 billion to shareholders. This included approximately $2.4 billion in share repurchases, with $183 million repurchased in Q4 using proceeds from recent tariff refunds.

We also paid $1.2 billion in dividends and earlier this
morning announced our 55th consecutive year of dividend increases. Finally, we paid down $2.4 billion in debt and ended the year with $2.7 times net leverage. Moving to our fiscal twenty seven guidance. Starting with revenue, we expect low single-digit growth for the full year. Based on current spot rates, currency is estimated to be a headwind of about 70 basis points.

As previously discussed, this reflects an approximate 200 basis points impact from the Alaris Capital comparison. Excluding this impact, we expect
mid-single-digit growth at the midpoint of our guidance. Moving down the PL, we expect adjusted operating margins to be roughly flat year over year. Our adjusted tax rate is expected to be between 16 and 17%. Weighted average shares outstanding for the full year are expected to be approximately $273 million.

Adjusted EPS is expected to be in a range
?of $13.10 to $13.30.

Passages & reports (23)
  • growth was
  • driven by share
  • gains and health utilization across the vascular access management portfolio. In specimen …
  • Connected care grew 2.1%, led by double digit growth in advanced patient monitoring, with …
  • delivered mid-single-digit growth, driven by strong infusion sets performance from Alaris …
  • vaccine headwind. Interventional grew 7.6%, with high single-digit growth in peripheral in…
  • launches. UCC was led by continued double-digit growth in PURIC, while surgery benefited f…
  • up 180 and 280 basis points respectively versus the prior year. Margins benefited from pro…
  • up 27.3% and ahead of our expectations, reflecting our strong revenue performance and disc…
  • For
  • the full year, adjusted growth margin was 55.1% and adjusted operating margin was 25%, dow…
  • and favorable mix. Adjusted EPS was $12.70, up 6.7%. Turning to cash flow and capital allo…
  • and
  • the momentum heading into 27. Improving free cash flow conversion is expanding our financi…
  • prior year. This reflects lower working capital and non operating cash items such as allow…
  • year. In
  • fiscal 26, we returned $3.6 billion to shareholders. This included approximately $2.4 bill…
  • morning announced our 55th consecutive year of dividend increases. Finally, we paid down $…
  • low single-digit growth for the full year. Based on current spot rates, currency is estima…
  • mid-single-digit growth at the midpoint of our guidance. Moving down the PL, we expect adj…
  • expected to be approximately $273 million. Adjusted EPS is expected to be in a range
  • of
  • $13.10 to $13.30.

Speaker unclear

?As

Passages & reports (1)
  • As

Speaker 3

you think about fiscal 27 phasing, we expect Q1 revenue growth to be at the low end of the range, with the first half expected to be in line with the midpoint of our full year guidance. As for earnings, given our Q1 revenue seasonality, annualization of last year's commercial investments and inflationary impacts, we expect Q1 adjusted EPS to be between $2.32 and $2.37.

We expect earnings growth to accelerate in Q2 and the second half of the
?year. With that, I'll turn it back to Tom. ?Thanks, Vitor. Before we open

Passages & reports (6)
  • you think about fiscal 27 phasing, we expect Q1 revenue growth to be at the low end of the…
  • inflationary impacts, we expect Q1 adjusted EPS to be between $2.32 and $2.37. We expect e…
  • year.
  • With that, I'll turn it back to Tom.
  • Thanks,
  • Vitor. Before we open

Speaker 2

the call for questions, I want to take a moment to recognize our associates around the world. Completing the life sciences separation while simultaneously executing against our new BD strategy required tremendous focus and commitment across the organization. Our strong finish to Fiscal 26 reflects their work, ?and I want to thank each of our associates for everything you've ?done. We enter Fiscal 27 with a more focused portfolio, clear priorities, and confidence in the long-term growth, earnings, and cash flow potential of the new BD.

With that, let's begin the QA. Operator, please open the line for questions.

Passages & reports (6)
  • the call for questions, I want to take a moment to recognize our associates around the wor…
  • their work,
  • and
  • I want to thank each of our associates for everything you've
  • done. We
  • enter Fiscal 27 with a more focused portfolio, clear priorities, and confidence in the lon…

Speaker 0

At this time, if you have a question, please press star one. If at any point your question is answered, you may remove yourself from the queue by pressing star two. In order to allow for broad participation, please limit yourself to only one question. Lastly, to provide optimal sound quality, please pick up your handset while you ask your question. Thank you. Our first question is from Patrick Wood with UPS.

Please go ahead.

Passages & reports (2)
  • At this time, if you have a question, please press star one. If at any point your question…
  • handset while you ask your question. Thank you. Our first question is from Patrick Wood wi…

Questions & answers

Speaker 4

Unverified voice label

Amazing. Thanks so much for taking the question, guys. If I take a step back and look at it, it looks like a decent chunk of the growth that you guys have is coming from investments, you know, stuff like the Salesforce in PI and things like that, helping you to take share. And so I guess, ?you know, I'm sure you'll chat about it more at the Inverse today, But big picture, how are you thinking about, you know, the rate of investment to help drive that top line relative to margins?

And is it just that you know you've got a flywheel going on PD Excellence that enables that recycling? Just how
are you thinking about the interplay between the investment for the top line and then and then the margin structure? Big picture. Thanks.

Passages & reports (5)
  • Amazing. Thanks so much for taking the question, guys. If I take a step back and look at i…
  • I guess,
  • you know,
  • I'm sure you'll chat about it more at the Inverse today, But big picture, how are you thin…
  • are you thinking about the interplay between the investment for the top line and then and …

Speaker unclear

?Hey,

Passages & reports (1)
  • Hey,

Speaker 2

good morning, Patrick, and thanks for the question. And uh I'll start off and then can turn it over to uh to Vitor. We we are, as you said, really pleased with the momentum that we're seeing, particularly in the growth drivers that we've been investing behind. You could see Exolaris about 7% growth in the quarter, led across essentially all of our growth platforms, you know, performed very strong.

And where we've been investing, we invested in the APM sales team. We saw a near 20-year high in the quarter. Certainly those investments help fuel that. Same thing in PI, same thing in UCC, obviously, capacity investments that
we had made in the past in our biologic capacity in farm systems you're seeing play out with a strong quarter there at 7% growth driven ?by our biologic business and some stabilization of the vaccine space. ?

So
we're going to continue focused investments there. Obviously, you know, we we obviously absorbed tariffs this year, which was meaningful. We expanded margins outside of that. ?And we're going to continue to take a prudent approach to making targeted investments behind our growth levers. We've reallocated RD as well behind those growth levers. We've been doing that over the last several years or seeing those pay off.

We're gonna look forward to sharing
?more on our pipeline and the momentum in that at analyst day on December tenth. Um but we expect that we will right um continue to do uh we will continue to drive operating margin expansion as we go forward as well. Obviously, again, you've got a tariff dynamic this year and then the Alaris grow over. But as that normalizes, we're gonna continue to see um ?the mixed benefits of that growth, the growth drivers that that we're investing behind, because they all come with accretive gross margins to the company.

So the larger that those gross platforms become a percentage of our revenue, actually it has a flywheel effect on our gross margin. Obviously BD Excellence has a flywheel effect on
our gross margin. And then that flows through ?you know the PL as we continue to be very prudent. You saw the cost actions that we took on GNA we continue to to do additional work there as we're streamlining and simplifying and focusing the company very aggressively as part of new B D and then making targeted investments in in selling as well.

So speed or other

Passages & reports (18)
  • good morning, Patrick, and thanks for the question. And uh I'll start off and then can tur…
  • the quarter, led across essentially all of our growth platforms, you know, performed very …
  • we had made in the past in our biologic capacity in farm systems you're seeing play out wi…
  • by
  • our biologic business and some stabilization of the vaccine space.
  • So
  • we're going to continue focused investments there. Obviously, you know, we we obviously ab…
  • And
  • we're going to continue to take a prudent approach to making targeted investments behind o…
  • more
  • on our pipeline and the momentum in that at analyst day on December tenth. Um but we expec…
  • over. But as that normalizes, we're gonna continue to see um
  • the
  • mixed benefits of that growth, the growth drivers that that we're investing behind, becaus…
  • our gross margin. And then that flows through
  • you
  • know the PL as we continue to be very prudent. You saw the cost actions that we took on GN…
  • So speed or other

Speaker 3

no, uh um I will just compliment. I think we we are very happy with the investments we have made during FY26. I think it's that clearly we do uh generating results from a top line perspective but also on the bottom line perspective given uh Tom was explaining we were able to cover topics like tariffs and and other types of pressures we had to navigate.

But when we see our advanced patient monitoring businesses growing double digit in FY26, our uh PI Salesforce expansion continue to result uh very strong growth. Those are all going to be accredited for
?us as we move forward, not only in 27, but beyond 27 as well. 27, as we expected, we and is part of our plan, we are expecting to have uh an inflationary environment into our numbers, but our continued mix and efforts on BD Excellence will ?uh result the benefits of setting those and continue to expand our operating margins down the road.

Passages & reports (6)
  • no, uh um I will just compliment. I think we we are very happy with the investments we hav…
  • like tariffs and and other types of pressures we had to navigate. But when we see our adva…
  • us
  • as we move forward, not only in 27, but beyond 27 as well. 27, as we expected, we and is p…
  • uh
  • result the benefits of setting those and continue to expand our operating margins down the…

Speaker unclear

?Love

Passages & reports (1)
  • Love

Speaker 4

it. Thanks, guys.

Passages & reports (1)
  • it. Thanks, guys.

Speaker 2

Thanks, Patrick.

Passages & reports (1)
  • Thanks, Patrick.

Speaker 0

Thank you. And we'll move next to Travis Steed with Bank of America. Please go ahead.

Passages & reports (1)
  • Thank you. And we'll move next to Travis Steed with Bank of America. Please go ahead.

Speaker unclear

?Hey,

Passages & reports (1)
  • Hey,

Speaker 1

congrats on the recorder. ?Um good

Passages & reports (3)
  • congrats on the recorder.
  • Um
  • good

Speaker 5

Unverified voice label

morning. Uh maybe I'll ask on on the guidance. Um, ?you know, Q one obviously a focus this morning, uh I heard you say it was below the full year guide. I don't know if there's any more ?kind of quantification on the top line on Q one, but also just trying to understand, ?you know, I think um ?you know your guidance philosophy to you've been executing really well uh since you've been CFO. ?

So
how much of this is conservatism ?and then the Q1 being below, how much of this is just like functional stuff from like Alaris and and other stuff that's kind of very explainable.

Passages & reports (13)
  • morning. Uh maybe I'll ask on on the guidance. Um,
  • you know,
  • Q one obviously a focus this morning, uh I heard you say it was below the full year guide.…
  • kind
  • of quantification on the top line on Q one, but also just trying to understand,
  • you
  • know, I think um
  • you
  • know your guidance philosophy to you've been executing really well uh since you've been CF…
  • So
  • how much of this is conservatism
  • and
  • then the Q1 being below, how much of this is just like functional stuff from like Alaris a…

Speaker 3

Sure. Thanks Travis so yeah so I'm completing now my first full year as a CFO. I'm very happy with the results we have delivered to the organization and to the shareholders. The philosophy continues to be the same. I want to make sure that we have a guidance that is responsible and prudent and we can deliver during the year with upsides to our shareholders.

If we think about Q1 specifically, there are a few dynamics there that is important that are important to explain. So first, we have very good momentum coming out of Q4, and that momentum is continuing as we head into Q1. If we see
segments like biopharma or interventional ?or even medical essentials, we continue to see good momentum there. What we have in Q1 is a dynamic with the Alaris, as you mentioned.

We mentioned that Alaris is about 200 basis points of pressure for the year. In Q1, Alaris is more acute than the rest of the year, about 250 basis points just
in Q1. That puts a little bit of a pressure on the connected care number. We also have a dynamic happening because on our APM business, we'll first we have very great momentum in APM.

We continue to be solid. And we are coming to the conclusion of our integration, and now we are going
live with the systems inside APM. So we took a prudent approach to make sure that we reflect that like scale of the new system in during Q1. So that's another impact we have in Q1 that is putting our growth rate at about the low end of the range.

But in general, the momentum
is very positive. The orders are very coming in. And the APM actually, we are tracking this on a daily basis now. We have very good momentum. We are seeing orders coming and actually shipments happening. We just took a conservative approach from an APM perspective. But other than the MMS situation and the APM, we feel very good about the numbers, the underlying uh of the other segments we have in the Q1 as well.

Passages & reports (9)
  • Sure. Thanks Travis so yeah so I'm completing now my first full year as a CFO. I'm very ha…
  • we can deliver during the year with upsides to our shareholders. If we think about Q1 spec…
  • segments like biopharma or interventional
  • or
  • even medical essentials, we continue to see good momentum there. What we have in Q1 is a d…
  • in Q1. That puts a little bit of a pressure on the connected care number. We also have a d…
  • live with the systems inside APM. So we took a prudent approach to make sure that we refle…
  • is very positive. The orders are very coming in. And the APM actually, we are tracking thi…
  • we feel very good about the numbers, the underlying uh of the other segments we have in th…

Speaker 2

I think you nailed it clearly as and as as Vitor shared, right, is it's really those two factors. We see strong momentum continuing across the company, a little bit higher grow over in Alaris, and then the APM. And I think you know, kudos to Vitor, as we again, we we're really pleased, we've had a lot of focus. Vitor's brought around our forecasting process, and we want to make sure that we continue that and set it up right in going into 27.

And I think the you know, with APM it's a big cut over from the Edward system going live, you know, for us.
?Um many times companies don't kind of plan that in their numbers. We assumed, hey, we want to make sure if everything doesn't go perfectly smooth, you know, we're gonna assume that, you know, some room in that. And so we're orders are still coming in.

There's no demand difference at all. It's just we may
end up shipping a bit more in Q two than in Q one with that. Now with that said, we actually went live this week and things are going as as planned. So right there could be actually, you know, it's we'll we'll continue to play that out. And if it goes even better than than we expected, we could see a little bit more rebalancing between Q one and Q two on the positive of Q one.

Um
?but we'll again we want to take a prudent approach to do that the right way starting FY twenty seven. But those are the only those are the two dynamics.

Passages & reports (8)
  • I think you nailed it clearly as and as as Vitor shared, right, is it's really those two f…
  • had a lot of focus. Vitor's brought around our forecasting process, and we want to make su…
  • Um
  • many times companies don't kind of plan that in their numbers. We assumed, hey, we want to…
  • end up shipping a bit more in Q two than in Q one with that. Now with that said, we actual…
  • than we expected, we could see a little bit more rebalancing between Q one and Q two on th…
  • but
  • we'll again we want to take a prudent approach to do that the right way starting FY twenty…

Speaker 5

Thanks a

Passages & reports (1)
  • Thanks a

Speaker unclear

?lot.

Passages & reports (1)
  • lot.

Speaker 2

Yep.

Passages & reports (1)
  • Yep.

Speaker 0

Thank you. ?And we'll move next to BA Kumar with Evercore ISI. Please

Passages & reports (3)
  • Thank you.
  • And
  • we'll move next to BA Kumar with Evercore ISI. Please

Speaker 1

Hi, Tom. Good

Passages & reports (1)
  • Hi, Tom. Good

Speaker unclear

?morning, and thank you for taking

Passages & reports (1)
  • morning, and thank you for taking

Speaker 1

my question. Congrats on the nice sprint here.

Passages & reports (1)
  • my question. Congrats on the nice sprint here.

Speaker 3

Tom, I just

Passages & reports (1)
  • Tom, I just

Speaker unclear

?want to go back on this performance here in Q4 in a five and a half ish,

Passages & reports (1)
  • want to go back on this performance here in Q4 in a five and a half ish,

Speaker 3

you know, close to six.

Passages & reports (1)
  • you know, close to six.

Speaker 1

Any

Passages & reports (1)
  • Any

Speaker unclear

?any

Passages & reports (1)
  • any

Speaker 3

one timers or timing,

Passages & reports (1)
  • one timers or timing,

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 1

know,

Passages & reports (1)
  • know,

Speaker 3

because this came in well about, you know, just look at the ?uh back half of twenty six performance. You guys have done five

Passages & reports (3)
  • because this came in well about, you know, just look at the
  • uh
  • back half of twenty six performance. You guys have done five

Speaker 1

organic, inclusive of head

Passages & reports (1)
  • organic, inclusive of head

Speaker 3

winch rates. So with with that kind of execution, why is two or two and a half percent the right number for uh fiscal uh 27? Thank ?you. Yeah, hi Vijay, it's Vitor. Uh we are very pleased with the back half performance of the actually with the entire year performance in 26 with the acceleration of 5% on the back half of the year.

From going into 27, as we mentioned, we want to make sure that we take a prudent approach uh
from our guidance. Uh of course, we uh Tom mentioned, I'm expanding a lot of time with the teams in terms of forecasting, making sure we have the right processes in place and and accuracy on our numbers. Alaris pressure increases, as I mentioned, 200 basis points with a more acute impact in the first half of the year.

But it's it's it's a matter of we making sure that we have a number that is a responsible guidance that we can deliver and even exceed during the year. That's what we are looking for heading into FY27.

Passages & reports (5)
  • winch rates. So with with that kind of execution, why is two or two and a half percent the…
  • you. Yeah,
  • hi Vijay, it's Vitor. Uh we are very pleased with the back half performance of the actuall…
  • from our guidance. Uh of course, we uh Tom mentioned, I'm expanding a lot of time with the…
  • half of the year. But it's it's it's a matter of we making sure that we have a number that…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

thanks for the question, BJ. But we we are very pleased with how those are executions playing out. And and again, as part of our our BD excellence strategy we've really doubled down on commercial excellence in FY26 right whether or not it's our comp plans um our hiring approaches our training approaches our our digital systems we are seeing benefits of that coming through complemented by you know it's physical expansion of of more people um ?you know selling behind our key growth platforms and and and you can see that momentum as it built through the back half of the year

Passages & reports (4)
  • thanks for the question, BJ. But we we are very pleased with how those are executions play…
  • digital systems we are seeing benefits of that coming through complemented by you know it'…
  • you
  • know selling behind our key growth platforms and and and you can see that momentum as it b…

Speaker unclear

?so thanks Tom

Passages & reports (1)
  • so thanks Tom

Speaker 0

you. ?And we will move next to Robbie Marcus with JP Morgan. Please go ahead.

Passages & reports (3)
  • you.
  • And
  • we will move next to Robbie Marcus with JP Morgan. Please go ahead.

Speaker 6

Unverified voice label

Uh congrats on the good quarter

Passages & reports (1)
  • Uh congrats on the good quarter

Speaker unclear

?and uh thanks for taking the question. Uh

Passages & reports (1)
  • and uh thanks for taking the question. Uh

Speaker 6

maybe ?a more macro related one. Tom, you're very plugged in through AVMed into DC. The sector was was up a lot uh yesterday on on the blue wave. You know, maybe speak to any of the immediate or intermediate term changes that you could foresee with Congress held by the Democrats. And then also maybe on the other side of the world in Europe and China, just speak to any trends you're seeing from healthcare policy.

We've heard a number of your competitors talk
about negative pricing in China. It'd be great just to get a global overview. Thanks.

Passages & reports (5)
  • maybe
  • a
  • more macro related one. Tom, you're very plugged in through AVMed into DC. The sector was …
  • you could foresee with Congress held by the Democrats. And then also maybe on the other si…
  • about negative pricing in China. It'd be great just to get a global overview. Thanks.

Speaker 2

Yeah thanks for the question, Raleigh. So just from a US perspective, maybe I I can start with just some utilization comments and and then convention on the the political side and then we can go around to the rest of the world. Um just from uh a utilization perspective, obviously we've got a very unique view there as as you know very well, ?um, as our products are used across essentially all types of procedures and all care settings.

And so particularly indicators like our blood collection tubes, syringes, catheters, kind of core products that have broad use, they're fantastic utilization um indicators. You know, we it in that regard, you know, we we continue to see strong utilization
in the U.S. uh USMDS 4%. That's a solid number, and and uh SM was 9% growth. ?Uh a bit of that was because we we've had new capacity come online and some competitive share gain, but underlying ?that was still very solid, and we continue to see more tubes collected per patient, which is an indicator that we're seeing more testing going on, which is a good sign of healthcare utilization.

Capital, you know, we continue to see it constructive, I'd say, but selective, and they're prioritizing high ROI investments. You know, we're
seeing that come through in really robust growth in our pharmacy automation business. We're seeing it come through with Pixys Pro doing very well. Um, and you heard us comment that we have a 100% attachment rate of our new AI platform, which is an upcharge from Pixas Pro.

Everyone's choosing it though. Um and
that AI platform is bringing new capabilities that help customers reduce their inventory levels, improve their cash flows, improve service levels for patients, for drug availability. And I think that's a that's also a new revenue stream from a SAS model that we're going to continue to be focused on building. But I think it's an indicator that again, the solutions that we have fit well with the needs of hospitals today and we're seeing strong, you know, continued capital placements.

APM had a great capital quarter and actually significant acceleration. and we don't see a slowdown in in that. Um as
we think about the the governments, obviously, you know, we've been around for 125 plus years. We work with any any uh ?uh party whoever's in office, we're focused on helping patients and helping advance health care. I think clearly there's been a perception that uh Democrats uh appreciate investing and the value of healthcare more broadly.

I'm assuming that's what happened yesterday, but we're focused on continuing to do our work around uh optimizing access for our
solutions and technologies. Obviously, we're focused on executing our tariff agreement with the the government, which doesn't change, and uh and making that come come through. And obviously that opportunity is not in our guide for FY twenty seven. And if two hundred thirty-two's are are implemented, would be you know an upside option that exists within our our current guide.

Um as we think about uh you know around the world and in China,
?you know, China's pretty stable for us. So ?uh I know there's organizations that have talked about it in their earnings that maybe it's new for them. Fortunately, unfortunately, it's not new for us. It's something we've been managing for a number of years. On a positive side, China now is a much smaller portion of B D.

We really don't see it as
a separate headwind this year. It's just part of our base business dynamic. It's kind of a continuation of last year. It's not an incremental item. And so we continue to we're just executing that, um, focusing on our commercial excellence and driving that, but we don't see that as anything incremental to us. And then in Europe, ?well, we saw strong performance in Europe.

And again, we're seeing strong partnerships with governments, particularly around medication management. We've had some great performance, you know, there is pharmacy automation in Europe. You heard us call out ROA. It did exceptionally well, double digits for both the quarter and
the year. Again, that's a labor improvement, a cost improvement. We see Europe actively consolidating um pharmacies both in the hospital and healthcare systems to these mega centers, which are all requiring our pharmacy robots to get put in place.

We're also seeing solid underlying demand on the consumable stream. And you you can see
that across our different businesses. So um, you know, we expect that to continue. I think our team feels good as we're going into twenty seven in in Europe as well. ?Um and we're not seeing a specific change uh against the solutions that we offer. So thank you for the

Passages & reports (29)
  • Yeah thanks for the question, Raleigh. So just from a US perspective, maybe I I can start …
  • unique view there as as you know very well,
  • um,
  • as our products are used across essentially all types of procedures and all care settings.…
  • in the U.S. uh USMDS 4%. That's a solid number, and and uh SM was 9% growth.
  • Uh
  • a bit of that was because we we've had new capacity come online and some competitive share…
  • that
  • was still very solid, and we continue to see more tubes collected per patient, which is an…
  • seeing that come through in really robust growth in our pharmacy automation business. We'r…
  • that AI platform is bringing new capabilities that help customers reduce their inventory l…
  • an indicator that again, the solutions that we have fit well with the needs of hospitals t…
  • we think about the the governments, obviously, you know, we've been around for 125 plus ye…
  • uh
  • party whoever's in office, we're focused on helping patients and helping advance health ca…
  • solutions and technologies. Obviously, we're focused on executing our tariff agreement wit…
  • exists within our our current guide. Um as we think about uh you know around the world and…
  • you
  • know, China's pretty stable for us. So
  • uh
  • I know there's organizations that have talked about it in their earnings that maybe it's n…
  • a separate headwind this year. It's just part of our base business dynamic. It's kind of a…
  • then in Europe,
  • well,
  • we saw strong performance in Europe. And again, we're seeing strong partnerships with gove…
  • the year. Again, that's a labor improvement, a cost improvement. We see Europe actively co…
  • that across our different businesses. So um, you know, we expect that to continue. I think…
  • Um
  • and we're not seeing a specific change uh against the solutions that we offer. So thank yo…

Speaker unclear

?question.

Passages & reports (1)
  • question.

Speaker 6

Thanks, Tom.

Passages & reports (1)
  • Thanks, Tom.

Speaker 0

Thank you. And we will move next to Matt Taylor with Jeffreys. Please go ahead.

Passages & reports (1)
  • Thank you. And we will move next to Matt Taylor with Jeffreys. Please go ahead.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 1

good morning. Thanks for taking the question. So I wanted to follow up on your partnership with the government. You noted the uh the shift in spending and potential relief from 232s. ?I know we don't know what the two thirty twos are going to look like, but wondered if you had any insight into that. And if they do come to pass, you know, how how does the relief work and and what's contemplated in your forward guidance uh in regards to the the agreement and and the tariff treatment specifically?

Passages & reports (4)
  • good morning. Thanks for taking the question. So I wanted to follow up on your partnership…
  • I
  • know we don't know what the two thirty twos are going to look like, but wondered if you ha…
  • the tariff treatment specifically?

Speaker 2

Sure. Yeah, thanks for the question, Matt. Um so a couple things. One is just to reiterate, uh, when we did receive refunds this year, that they were not um ?they were excluded from our adjusted results, right? So there is no grow over for us from a tariff refund. So that that's a positive, right? So any benefit on tariffs would flow through as a positive in our in our earnings.

Our initial guide assumes tariffs generally in line with FY26. So we have no
benefit of that that deal in our our current guide. And the rationale for that obviously is just because the 232's tariffs, the product scope and the effective timing hasn't been finalized, we didn't think it's appropriate to include that in our our outlook at this time. Obviously the government has made commentary that they would expect that to be in place by the end of the calendar year.

You know, we're staying in touch on that. But we're watching that just like you and and um if and when that is communicated, um, you know, we'll look to to provide an update to our guide at that that time.

Passages & reports (5)
  • Sure. Yeah, thanks for the question, Matt. Um so a couple things. One is just to reiterate…
  • they
  • were excluded from our adjusted results, right? So there is no grow over for us from a tar…
  • benefit of that that deal in our our current guide. And the rationale for that obviously i…
  • would expect that to be in place by the end of the calendar year. You know, we're staying …

Obviously, you know the the Section 232 tariffs are intended to cover med tech overall and which would include many of the products that we have and that we currently pay tariffs on. And as we've shared our agreement would be that any products that are in those two thirty twos that we would not pay any tariffs on. And so that would be an upside, you know, to to what our current assumptions are, if and when that occurs.

Um as you also said, it's not incremental spending for us. You know, we're reallocating investments that we've uh you know wouldn't typically
?make um globally ?and we've concentrated, you know, those in um not only in the US but often in in areas where we already have focus. So in Nebraska, you know, in in our Columbus plants, in uh in Texas in our El Paso plant, in South Carolina in our Sumter plant, et cetera.

And so we're going to
continue to uh to execute on those. There's also benefits even just from a global supply chain, as as many much of that is going to be servicing the US. And that actually brings up, you know, our ratio of the products that we make in the US and sell in the US within our Med Essentials portfolio, or those essential medical devices, to about 80%.

Right. And so that's a positive as well, too, as we think about shipping, et cetera.
?So um we'll stay, we'll we'll we'll uh keep everyone updated. Obviously as as soon as anything's announced on the two thirty twos, you know, we'll share implications of that is for BD, but I would view it as a positive option that's ?it's kind of built into our outlook right

Passages & reports (12)
  • Obviously, you know the the Section 232 tariffs are intended to cover med tech overall and…
  • pay any tariffs on. And so that would be an upside, you know, to to what our current assum…
  • make
  • um globally
  • and
  • we've concentrated, you know, those in um not only in the US but often in in areas where w…
  • continue to uh to execute on those. There's also benefits even just from a global supply c…
  • Med Essentials portfolio, or those essential medical devices, to about 80%. Right. And so …
  • So
  • um we'll stay, we'll we'll we'll uh keep everyone updated. Obviously as as soon as anythin…
  • it's
  • kind of built into our outlook right

Speaker unclear

?now.

Passages & reports (1)
  • now.

Speaker 1

Thanks so much, Tom

Passages & reports (1)
  • Thanks so much, Tom

Speaker 0

Thank you. ?And we'll move next to Larry Beagleson with Wells Fargo. Please go ahead.

Passages & reports (3)
  • Thank you.
  • And
  • we'll move next to Larry Beagleson with Wells Fargo. Please go ahead.

Speaker 1

Good morning. Thanks for taking the question. Congrats on a nice

Passages & reports (1)
  • Good morning. Thanks for taking the question. Congrats on a nice

Speaker unclear

?quarter here. So, Tom, you have uh an analyst day coming up in December, the first one in a while. Um, I'd love to get a quick preview and you know to

Passages & reports (1)
  • quarter here. So, Tom, you have uh an analyst day coming up in December, the first one in …

Speaker 5

help set expectations. I I think the expectation

Passages & reports (1)
  • help set expectations. I I think the expectation

Speaker unclear

?is for you know return to

Passages & reports (1)
  • is for you know return to

Speaker 5

mid-single digit growth once ?the Alaris headwind goes away in fiscal twenty-eight.

Passages & reports (3)
  • mid-single digit growth once
  • the Alaris
  • headwind goes away in fiscal twenty-eight.

Speaker 7

Unverified voice label

Is that fair? And do you think you can you know get leverage on the PL uh after fiscal twenty-seven? Thank

Passages & reports (1)
  • Is that fair? And do you think you can you know get leverage on the PL uh after fiscal twe…

Speaker unclear

?you. Yeah,

Passages & reports (1)
  • you. Yeah,

Speaker 2

thanks, Larry, for the question.

Passages & reports (1)
  • thanks, Larry, for the question.

And sometimes we joke that the some of what we share financially may not be overly exciting because it's in line with just what you said, right? We we will be communicating and expect um we'll be back at mid-single digit growth, just like we are we were in in FY26, you know, Exolaris headwind. We were, ?you know, about five percent growth. Our current guide at the midpoint is mid-single digit growth starting the year, um, Exolaris headwind, and the Ilaris headwind goes away as we go into to next year and right with that um we will would expect just the straightforward all in number will be Xolaris headwind and it'll be mid-single digit.

Um and we do expect obviously there's about 500 basis points of earnings
?uh EPS pressure from the Alaris headwind this year. That also goes away um as we go into next year. And so you know we will absolutely have margin expansion, you know ?uh as as part of what we'll share at earnings. That's in line with what we've been communicating mid-single digits with solid continued margin expansion, increasing cash flow, and a very disciplined approach to value creation with that cash flow. ?

So
we're excited for the upcoming event. It's an important moment for us to cli to provide clarity on the next phase of growth for BD. We're going to provide you an update with a strategic update on overall our portfolio. We'll go deeper and highlight those key growth areas of the business that we've been investing behind. We'll reveal some new innovations in that space that we haven't shared to date that we're excited to buy. ?

We'll
give an update on BD excellence and how we're applying it not just in operations and how it's going to drive continued growth and operating margin expansion over the mid and long term, but also how it's benefiting us in RD and how it's going to be benefiting us increasingly in commercial. And you started seeing that happen this year. We'll double click into our capital allocation framework, which is in line with what we've already communicated.

And we're going to give long-term financial targets that that govern that strategy.
?So we've got a product showcase as well planned that uh folks will be able to walk through and touch and feel and discuss you know our innovations firsthand. And I'm confident that the event's gonna only add conviction ?to our investment thesis. So we'll look forward to seeing you and and uh and everyone else

Passages & reports (19)
  • And sometimes we joke that the some of what we share financially may not be overly excitin…
  • We were,
  • you
  • know, about five percent growth. Our current guide at the midpoint is mid-single digit gro…
  • be mid-single digit. Um and we do expect obviously there's about 500 basis points of earni…
  • uh
  • EPS pressure from the Alaris headwind this year. That also goes away um as we go into next…
  • uh
  • as as part of what we'll share at earnings. That's in line with what we've been communicat…
  • So
  • we're excited for the upcoming event. It's an important moment for us to cli to provide cl…
  • investing behind. We'll reveal some new innovations in that space that we haven't shared t…
  • We'll
  • give an update on BD excellence and how we're applying it not just in operations and how i…
  • seeing that happen this year. We'll double click into our capital allocation framework, wh…
  • So
  • we've got a product showcase as well planned that uh folks will be able to walk through an…
  • to
  • our investment thesis. So we'll look forward to seeing you and and uh and everyone else

Speaker unclear

?there.

Passages & reports (1)
  • there.

Speaker 5

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Thank you. And we'll move next to Josh Jennings with TD Cohen. Please go ahead.

Passages & reports (1)
  • Thank you. And we'll move next to Josh Jennings with TD Cohen. Please go ahead.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 1

good morning,

Passages & reports (1)
  • good morning,

Speaker unclear

?Tom and Vitor. Thanks for taking the questions and echo the congratulations on a strong quarter.

Passages & reports (1)
  • Tom and Vitor. Thanks for taking the questions and echo the congratulations on a strong qu…

Speaker 7

Wanted to just um touch on biologics, one of the largest potential long-term growth opportunities in healthcare. BD's very well positioned to capitalize. And how should investors think about the durability of growth ?for your bare biologics franchise, GLP ones and beyond GLP ones? Thanks for taking the question.

Passages & reports (3)
  • Wanted to just um touch on biologics, one of the largest potential long-term growth opport…
  • for
  • your bare biologics franchise, GLP ones and beyond GLP ones? Thanks for taking the questio…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

thanks, Josh. Um you saw strong performance in in biologics throughout

Passages & reports (1)
  • thanks, Josh. Um you saw strong performance in in biologics throughout

Speaker 3

FY26, and we expect continued strong performance through 27 and beyond. ?I think we're really pleased, A, with the portfolio of GOP1s that we have, both uh partners that we work with today who continue to do very well, um,

Passages & reports (3)
  • FY26, and we expect continued strong performance through 27 and beyond.
  • I
  • think we're really pleased, A, with the portfolio of GOP1s that we have, both uh partners …

Speaker 2

but

Passages & reports (1)
  • but

Speaker 3

also the portfolio

Passages & reports (1)
  • also the portfolio

Speaker 2

that we've

Passages & reports (1)
  • that we've

Speaker 3

built of the new

Passages & reports (1)
  • built of the new

Speaker 2

novel molecules coming to market, which we have a very high share in from a win rate perspective, and and also the biosimilars.

Passages & reports (1)
  • novel molecules coming to market, which we have a very high share in from a win rate persp…

Speaker 3

And we are

Passages & reports (1)
  • And we are

Speaker 2

starting to see benefits, and we'll see a bit more of benefits of biosimilars in FY27 than we saw in 26. And I think the first one of meaningful size is the

Passages & reports (1)
  • starting to see benefits, and we'll see a bit more of benefits of biosimilars in FY27 than…

Speaker 3

uh is in Brazil. We put out a press release on ?that. And what happens, we're gonna see just what we've said, as products go to biosimilars, we not only can capture the syringe itself inside, but we also have the opportunity to capture the auto injector,

Passages & reports (3)
  • uh is in Brazil. We put out a press release on
  • that.
  • And what happens, we're gonna see just what we've said, as products go to biosimilars, we …

Speaker 2

which is several times higher ASP.

Passages & reports (1)
  • which is several times higher ASP.

Speaker 3

And for example, our Brazil partnership is for

Passages & reports (1)
  • And for example, our Brazil partnership is for

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 2

Penn, which again is several times higher per unit value that we capture than if we were just selling a syringe. So we've got more of those coming. Again, we've signed down nearly 100 um deals in in that space, and

Passages & reports (1)
  • Penn, which again is several times higher per unit value that we capture than if we were j…

Speaker 3

we'll expect those to continue to roll out over the years ahead. But we do see some of that starting in FY27, and that'll be a positive.

Passages & reports (1)
  • we'll expect those to continue to roll out over the years ahead. But we do see some of tha…

Speaker 3

very high win rate in biologics overall, one of the highest win rates of any product line in the company, in fact. Our solutions are very unique there, whether or not it's our XSI crosslink coatings that we use for biologics, our unique needle technology for biologics, or our Neopak product line, which is best in class there. And we see people standardizing on it for biologics.

And obviously, we've got capacity that we invested in. We made a pretty bold decision a couple of years ago to put a billion two in capacity. That was right during the middle of the pandemic. I know we got questions then when
we did it, but we're seeing it pay off because we've got state-of-the-art lines now that are producing really high quality product, which is really important for these high-value biologics, and it's it's helping fuel that win rate.

So, you know, again, we we saw good performance in the quarter. You know, we expect that
to continue as we go into to Q1, as VTOR mentioned. We expect farm systems to continue to ?have that very strong performance. ?I think maybe just one other thing I'd say on farm systems, and it wasn't in the question, but ?you know, we did see, we do expect um vaccines to not be a topic that we're talking about in 27.

Um it moderated in the quarter. It still had a decline, uh, vaccines declined about 11% in Q4. So, you know, basically more than cut

Passages & reports (10)
  • very high win rate in biologics overall, one of the highest win rates of any product line …
  • in class there. And we see people standardizing on it for biologics. And obviously, we've …
  • we did it, but we're seeing it pay off because we've got state-of-the-art lines now that a…
  • to continue as we go into to Q1, as VTOR mentioned. We expect farm systems to continue to
  • have
  • that very strong performance.
  • I
  • think maybe just one other thing I'd say on farm systems, and it wasn't in the question, b…
  • you
  • know, we did see, we do expect um vaccines to not be a topic that we're talking about in 2…

Speaker 2

in half what we had seen

Passages & reports (1)
  • in half what we had seen

Speaker 3

prior in the year. But we expect that to basically totally dissipate

Passages & reports (1)
  • prior in the year. But we expect that to basically totally dissipate

Speaker 2

in FY27 and not be a headwind to the farm systems business. So we see that as a positive. Really, the only

Passages & reports (1)
  • in FY27 and not be a headwind to the farm systems business. So we see that as a positive. …

Speaker 3

thing for 27 is is Alaris, you know, grow over. And we're going to continue to gain share in Alaris. We continue to do extremely well there. It's not a performance topic. And we'll we'll see that totally disappear as we go in the 28th. Thanks for the question, Josh.

Passages & reports (1)
  • thing for 27 is is Alaris, you know, grow over. And we're going to continue to gain share …

Speaker 0

Thank you. ?And we'll move next to Joanne Wounch with Citibank. Please go ahead. Thank you for taking the question in

Passages & reports (3)
  • Thank you.
  • And
  • we'll move next to Joanne Wounch with Citibank. Please go ahead. Thank you for taking the …

Speaker unclear

?a nice quarter. Two quick questions. Your guidance for fiscal year 27 is for operating markets to be flat year over year, and I appreciate the commentary that that should resume expansion in the following year. Can you tease out a little bit between growth margins and operating expenses so we can really maybe think

Passages & reports (1)
  • a nice quarter. Two quick questions. Your guidance for fiscal year 27 is for operating mar…

Speaker unclear

?about the components of that? And then my second question has to do with AI. That those

Passages & reports (1)
  • about the components of that? And then my second question has to do with AI. That those

Speaker 7

initials ?are being sprinkled in

Passages & reports (3)
  • initials
  • are
  • being sprinkled in

Speaker 0

here and there as I'm talking to more and more medical technology ?companies and

Passages & reports (3)
  • here and there as I'm talking to more and more medical technology
  • companies
  • and

Speaker unclear

?hoping you can sort of give your view on how that can help your business

Passages & reports (1)
  • hoping you can sort of give your view on how that can help your business

Speaker 0

and your patients.

Passages & reports (1)
  • and your patients.

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker 3

Sure. I'll I'll start with the margin, uh Joanne. So we are very pleased with the efforts we did in 26, and those efforts are going to continue in 27. Our margin, uh gross margin and operating margin, as we mentioned, is going to be roughly flat. ?And it's going to be similar between gross profit and operating margin. So there's not going to be a big difference there.

We continue to make some strategic investments on our commercial and R D organizations to continue to kind of uh feed the flywheel of positive growth on the platforms we have. So we are
not hindering any investments that are going to drive that future growth. We expect, but we expect GP to be roughly at the same level as operating margin, roughly flat. And that's we have um, as we mentioned before, we expect 27 to be uh inflationary environments.

And that's according to what we have said,
nothing has changed from our assumption there. So that was part of our our uh guidance and plan all along. Um but our um initiatives around BD excellence with supply chain but also our capacity of increasing prices are going to be used in order to kind of mitigate those headwinds we have from an inflation perspective.

Um an operating margin we continue to do the investments. I think it's important to remember the Alaris impact on our on our margins. It's as Tom said it's about 500 basis points on EPS, but also in margin, we are talking about 60 basis points of pressure from Alaris on our
operating margin. So excluding that we will be actually expanding the margins in FY27 as well.

So we feel very good about the the buckets of where we are heading into FY27 from a margin perspective. We feel that we have all the plans in place
?and we are going to continue to execute them during 27. Thanks for the

Passages & reports (9)
  • Sure. I'll I'll start with the margin, uh Joanne. So we are very pleased with the efforts …
  • And
  • it's going to be similar between gross profit and operating margin. So there's not going t…
  • not hindering any investments that are going to drive that future growth. We expect, but w…
  • nothing has changed from our assumption there. So that was part of our our uh guidance and…
  • inflation perspective. Um an operating margin we continue to do the investments. I think i…
  • operating margin. So excluding that we will be actually expanding the margins in FY27 as w…
  • and
  • we are going to continue to execute them during 27. Thanks for the

Speaker 2

question also on AI, Joanne. I can address that. So, you know, we we do see significant opportunities from AI, and we've spent a lot of time focusing specifically where we want to apply that to maximize return and value creation. ?You know, on the RD innovation, we'll share more at Investor Day, ?but obviously the launch of our Ancata um AI platform for all of our products in BD is a major milestone in that.

And again, we're seeing 100% attachment rate now on all new Pixis placements, which is going to be embedding that
?you know across healthcare systems quite rapidly. All

Passages & reports (7)
  • question also on AI, Joanne. I can address that. So, you know, we we do see significant op…
  • You
  • know, on the RD innovation, we'll share more at Investor Day,
  • but
  • obviously the launch of our Ancata um AI platform for all of our products in BD is a major…
  • you
  • know across healthcare systems quite rapidly. All

Speaker 3

BD products

Passages & reports (1)
  • BD products

Speaker 2

will end up feeding their data into Encata. And we have plans to continue to not only have that be a solution for our customers to reduce costs, but also improve clinical outcomes. And we'll share more ?about our roadmap and the types of indications that we'll be going after there. But imagine it's some of that will be in line with what we've talked about in the past, including taking data from sensors on patients that we have now access to from APM with all of the drug delivery information that we have from our platforms and looking to improve patient outcomes there while also improving costs from drug inventory, drug waste, um, and and availability to improve uh nursing workflow.

Um beyond uh what we're doing in AI in in products, you know, and APM is that's actually a big far part of their growth,
are all the APM uh AI algorithms that they've been deploying that are helping improve patient care. But we're also applying AI within the company to uh to make us more efficient and to deliver better outcomes. Um we've focused on a few specific areas there

Passages & reports (5)
  • will end up feeding their data into Encata. And we have plans to continue to not only have…
  • about
  • our roadmap and the types of indications that we'll be going after there. But imagine it's…
  • have from our platforms and looking to improve patient outcomes there while also improving…
  • are all the APM uh AI algorithms that they've been deploying that are helping improve pati…

Speaker 3

rather than just

Passages & reports (1)
  • rather than just

Speaker 2

peanut butter

Passages & reports (1)
  • peanut butter

Speaker 3

spreading ?it. And one of the

Passages & reports (3)
  • spreading
  • it.
  • And one of the

Speaker 2

number one areas is in manufacturing. We've communicated that we've

Passages & reports (1)
  • number one areas is in manufacturing. We've communicated that we've

Speaker 3

recently

Passages & reports (1)
  • recently

Speaker 2

begun

Passages & reports (1)
  • begun

Speaker 3

deploying

Passages & reports (1)
  • deploying

Speaker 2

a new AI

Passages & reports (1)
  • a new AI

Speaker 3

platform

Passages & reports (1)
  • platform

Speaker 2

across the company. We shared our product name ?for it. It's the Cognite platform, though, is the AI platform that we're deploying across manufacturing. And that really is an end-to-end platform that is going to help us automate and improve everything from the demand

Passages & reports (3)
  • across the company. We shared our product name
  • for
  • it. It's the Cognite platform, though, is the AI platform that we're deploying across manu…

Speaker 3

planning

Passages & reports (1)
  • planning

Speaker 2

to the production planning to the inventory levels to supply levels to our customers. We've begun deploying that across our manufacturing plants, and we see that in partnership with BD

Passages & reports (1)
  • to the production planning to the inventory levels to supply levels to our customers. We'v…

Speaker 3

Excellence as helping to catalyze the next phase of opportunity for us from a cost efficiency perspective and a cash flow perspective. So and it's also allowing us to get rid of a lot of other platforms at the same time as we consolidate

Passages & reports (1)
  • Excellence as helping to catalyze the next phase of opportunity for us from a cost efficie…

Speaker 2

that from an

Passages & reports (1)
  • that from an

Speaker 3

IT tech stack perspective.

Passages & reports (1)
  • IT tech stack perspective.

Speaker 2

The second major area that we're focused on is our tech stack within our sales organization. And we've started using AI in everything from our hiring and screening practices. We've got this really interesting new tool that we're using and standardizing on that uses AI to understand the behaviors of sales reps that we're hiring and making

Passages & reports (2)
  • The second major area that we're focused on is our tech stack within our sales organizatio…
  • and making

Speaker 3

sure

Passages & reports (1)
  • sure

Speaker 2

that

Passages & reports (1)
  • that

Speaker 3

they match the characteristics that we've done research on that match with the highest performing reps and making sure that we're systematically bringing those on with no bias. We're using AI for sales planning

Passages & reports (1)
  • they match the characteristics that we've done research on that match with the highest per…

Speaker 2

so ?that they can practice and prep before they go visit with customers,

Passages & reports (3)
  • so
  • that
  • they can practice and prep before they go visit with customers,

Speaker 3

as well as helping them analyze the sales performance data and identifying information to tee up to our sales team where there's opportunities

Passages & reports (1)
  • as well as helping them analyze the sales performance data and identifying information to …

Speaker 2

or

Passages & reports (1)
  • or

Speaker 3

anything that they need to address

Passages & reports (1)
  • anything that they need to address

Speaker 2

so we can be

Passages & reports (1)
  • so we can be

Speaker 3

faster paced and

Passages & reports (1)
  • faster paced and

Speaker 2

more on top of the information. So

Passages & reports (1)
  • more on top of the information. So

Speaker 3

we're really excited about what we can do there on the commercial side.

Passages & reports (1)
  • we're really excited about what we can do there on the commercial side.

Speaker unclear

?We're

Passages & reports (1)
  • We're

Speaker 3

doing some things

Passages & reports (1)
  • doing some things

Speaker 2

on the RD side where we set some goals using AI where we can remove inefficiencies, particularly on our sustained engineering work that we ?do, which there's a lot, obviously, across the breadth of our portfolio, and simplifying that with AI. We have plans on being able to reallocate more sustaining engineering spend into new innovation spend, and AI is a piece of ?that. And then obviously, you know, over time there's opportunities on just GNA efficiencies.

But as part of that, I'd I'd also just call
?out that we

Passages & reports (7)
  • on the RD side where we set some goals using AI where we can remove inefficiencies, partic…
  • do,
  • which there's a lot, obviously, across the breadth of our portfolio, and simplifying that …
  • that.
  • And then obviously, you know, over time there's opportunities on just GNA efficiencies. Bu…
  • out
  • that we

Speaker 3

we spent a lot of time making sure that we have the capabilities to advance the new BD

Passages & reports (1)
  • we spent a lot of time making sure that we have the capabilities to advance the new BD

Speaker 2

in a way that fully leverages the opportunities of the technology that's becoming available today. And for us to be at the forefront of that within MedTech. And

Passages & reports (1)
  • in a way that fully leverages the opportunities of the technology that's becoming availabl…

Speaker 3

so

Passages & reports (1)
  • so

Speaker 2

this past year, we reallocated actually all of our central RD resources that were doing anything digital. We moved into the connected care business and we actually created an AI COE in Irvine, California that's under Bilal, and that's off to a

Passages & reports (1)
  • this past year, we reallocated actually all of our central RD resources that were doing an…

Speaker 3

great start. And we also brought in a new CIO, uh Art Who, who joined us from Lenovo, where he's got a ton of experience in this, obviously coming from the tech industry, which I think is certainly more advanced than we see med tech overall. And we're really pleased to have Art with us sharing his experience and his bar of excellence and opportunity that he sees in leveraging AI to

Passages & reports (2)
  • great start. And we also brought in a new CIO, uh Art Who, who joined us from Lenovo, wher…
  • sharing his experience and his bar of excellence and opportunity that he sees in leveragin…

Speaker 2

improve business performance and competitive advantage. So we're looking forward to continuing to provide more updates on that, but um but we certainly see opportunity there

Passages & reports (1)
  • improve business performance and competitive advantage. So we're looking forward to contin…

Speaker 3

and we'll share more

Passages & reports (1)
  • and we'll share more

Speaker 2

at uh at Analyst Day. Thanks, Joanne.

Passages & reports (1)
  • at uh at Analyst Day. Thanks, Joanne.

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker 0

Thank you. ?And we will move next to Michael Pilark with Wolf Research. Please go ahead.

Passages & reports (3)
  • Thank you.
  • And
  • we will move next to Michael Pilark with Wolf Research. Please go ahead.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 1

good morning. Thank you for taking the question. Um, Tom, I appreciated all the color already on Biofarm systems. I'm gonna ask one follow-up. Um, one of your large competitors earlier this week in glass packaging um cautioned ?uh on GLP1 revenue in 2027. Uh personally suggesting it will be down. Personally, I was stunned. Um category injectable categories growing a lot even with rise of orals and format shifts.

Um you sound more optimistic here uh on GLP ones for that business. C can you help further square
this? Um ?are you taking share? Is it something about customer mix or product mix? ?Uh and I'd welcome any further color about um kind of the the your enthusiasm still um and and the message from one of your competitors. Thank

Passages & reports (8)
  • good morning. Thank you for taking the question. Um, Tom, I appreciated all the color alre…
  • uh
  • on GLP1 revenue in 2027. Uh personally suggesting it will be down. Personally, I was stunn…
  • this? Um
  • are
  • you taking share? Is it something about customer mix or product mix?
  • Uh
  • and I'd welcome any further color about um kind of the the your enthusiasm still um and an…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Yeah, th thanks for the question, Michael. Um we don't obviously comment on on specific competitors, but uh what I can say is again, we're really pleased with our very high win rate in the category. Um It is exceptionally high for new molecules coming to market. It's very high for biosimilars. And customer mix is very important here, right? Obviously, there's companies in GLP one that are that ?are winning different differentially than others.

And
?you know, the mix that you have is

Passages & reports (6)
  • Yeah, th thanks for the question, Michael. Um we don't obviously comment on on specific co…
  • is very important here, right? Obviously, there's companies in GLP one that are that
  • are
  • winning different differentially than others. And
  • you
  • know, the mix that you have is

Speaker 2

is really important there. So just leave it at that. We continue to see ?you know solid growth in GLP one's looking forward.

Passages & reports (3)
  • is really important there. So just leave it at that. We continue to see
  • you
  • know solid growth in GLP one's looking forward.

Speaker 6

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Thank you. And we will move next to Chris Pascal with Barclays. Please go ahead.

Passages & reports (1)
  • Thank you. And we will move next to Chris Pascal with Barclays. Please go ahead.

Speaker unclear

?Thanks. Congrats on the quarter.

Passages & reports (1)
  • Thanks. Congrats on the quarter.

Speaker 1

Wanted to ask about capital allocation priorities in FY27. You got some more debt coming due this year. This morning you also announced incremental share repurchase authorization. And it looks like maybe there's a little bit of buyback assumed in the guidance. Can you walk through what's in the outlook in terms of use of cash and how you're going to prioritize debt pay down versus buybacks versus maybe getting a little bit more aggressive on the MA front this year.

Thanks.

Passages & reports (2)
  • Wanted to ask about capital allocation priorities in FY27. You got some more debt coming d…
  • cash and how you're going to prioritize debt pay down versus buybacks versus maybe getting…

Speaker 3

Thanks, Chris. Um, so we continue to be very focused on our capital allocation strategy. Earlier in 26, we mentioned that we are going to focus uh one of the top priorities of our capital allocation is share buybacks, and that has not changed. We will continue to execute that. Uh in 26, we as we mentioned on the prepared remarks, we returned more than two billion dollars to shareholders via share buybacks and dividends.

We plan to continue to dedicate an important part of our cash flow into share buybacks and return to the shareholders. Of course, debt pay down, it's also like achieving the net leverage that we
have been committing to is important. It's going to be a mix between debt pay down and uh increase on our income. But also we are leaving uh power for us to do focus tucking MA, which is a very important topic for us.

We're gonna continue to build our portfolio in order to be
that mid mid-single digit sustainable mid-single digit growth company. But the priorities on capital allocation have not changed since we started this year in 26. We continue to focus on uh share buybacks and uh focus on taquina MNA going forward as ?well. Thanks for the

Passages & reports (6)
  • Thanks, Chris. Um, so we continue to be very focused on our capital allocation strategy. E…
  • we mentioned on the prepared remarks, we returned more than two billion dollars to shareho…
  • have been committing to is important. It's going to be a mix between debt pay down and uh …
  • that mid mid-single digit sustainable mid-single digit growth company. But the priorities …
  • well.
  • Thanks for the

Speaker unclear

?question.

Passages & reports (1)
  • question.

Speaker 0

Thank you. ?And that will conclude today's question and answer session. At this time, I'd like to turn the floor back over to Tom Poland for any additional or closing remarks.

Passages & reports (3)
  • Thank you.
  • And
  • that will conclude today's question and answer session. At this time, I'd like to turn the…

Speaker 2

Thank you, Operator, and thanks everyone for your questions and your continued interest and support in BD. ?We look forward to seeing you all on December 10th at our investor day in New York City and hope you have a great rest of the ?day. Thank

Passages & reports (5)
  • Thank you, Operator, and thanks everyone for your questions and your continued interest an…
  • We
  • look forward to seeing you all on December 10th at our investor day in New York City and h…
  • day.
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Thank you. This does conclude this audio webcast. On behalf of BD, thank you for joining today. Please disconnect your lines at this time and have a wonderful day.

Passages & reports (1)
  • Thank you. This does conclude this audio webcast. On behalf of BD, thank you for joining t…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 0. Unassigned words: 338. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T20:23:26.295Z.
Transcript version v1-3318dae8fa4260679264 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.